Pembrolizumab in combination with umbralisib and ublituximab induced responses in 90% of patients with relapsed/refractory chronic lymphocytic leukemia, according to data from a phase I/II study presented at the 2018 ASH Annual Meeting. Additionally, a 50% response rate was also demonstrated in patients with Richter’s transformation.
After 7 years of follow-up, single-agent ibrutinib demonstrated continued efficacy in the frontline and heavily pretreated, relapsed/refractory settings for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Lisocabtagene maraleucel induced an 81.3% best overall response rate and 43.8% complete response in high-risk patients with chronic lymphocytic leukemia who were heavily pretreated and had previously received ibrutinib, according to dose-finding results presented at the 2018 ASH Annual Meeting.
Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of a phase II trial.<br />
According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
In a study of transplant-eligible patients with newly diagnosed multiple myeloma, daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients, including a complete response in 63% of patients, at the end of consolidation therapy.<br />
Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
According to a retrospective phase I/II study, over 80% of patients with relapsed or refractory chronic lymphocytic leukemia responded to concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor CAR T-cell therapy, JCAR014.<sup>1</sup> Findings from this study were presented at the 60th American Society of Hematology Annual Meeting.
The need for frequent red blood cell transfusions was reduced with luspatercept in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.
Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.
After a median of 19 months of follow-up, durable objective response rates were sustained with tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma. These updated findings from the phase II JULIET study were presented at the 2018 ASH Annual Meeting.
According to updated data from the phase II ELIANA study, CD19-targeted CAR T-cell therapy tisagenlecleucel as treatment of pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia sustained rates of relapse-free survival and overall survival at 24 and 18 months.
Progression-free survival was significantly improved with both ibrutinib as monotherapy and in combination with rituximab when compared to bendamustine plus rituximab as a treatment for older patients with newly diagnosed chronic lymphocytic leukemia. These data were presented at the 2018 ASH Annual Meeting.
Treatment of patients with advanced or metastatic cancers with the transforming growth factor-β receptor type 1 inhibitor LY3200882 demonstrated a tolerable safety profile and early signs of efficacy, according to the results from a first-in-human, dose-escalation phase I trial presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Results from a phase II trial of abemaciclib presented at the 2018 CTOS Annual Meeting showed that the majority of patients with dedifferentiated liposarcoma remained progression free at 12 weeks following abemaciclib treatment.
The addition of olaratumab to doxorubicin-based chemotherapy resulted in similar response and stable disease rates between patients with advanced soft tissue sarcoma and a good performance status, but provided an improved safety profile that favored the olaratumab cohort, according to results reported at the 2018 CTOS Annual Meeting.
Cabozantinib demonstrated the strongest response observed to date among all the multikinase inhibitors that have shown activity in bone sarcoma, according to results from the CABONE trial that were reported at the 2018 CTOS Annual Meeting.
Avapritinib showed substantial clinical activity in patients with gastrointestinal stromal tumors with <em>KIT</em> and <em>PDGFRA</em> mutations, according to findings from the phase I NAVIGATOR trial presented at the 2018 CTOS Annual Meeting. To date, patients with GIST who harbor these mutations have typically been resistant to all available therapies.
Half of the patients with inflammatory myofibroblastic tumor (IMFT) demonstrated a response to crizotinib (Xalkori), according to results from the EORTC phase II "CREATE" study 90101 reported at the 2018 CTOS Annual Meeting.
The investigational agent avapritinib demonstrated encouraging response rates in patients with advanced gastrointestinal stromal tumors and PDGFRα D842V-driven GIST, according to findings presented during the 2018 Annual Meeting of the Connective Tissue Oncology Society in Rome, Italy.
During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.
During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Jason Roszik, PhD, MBA, of the MD Anderson Cancer Center, discusses the use of next-generation sequencing in intimal sarcoma.<br />
Patrick Schöffski, MD, MPH, discussed the key findings from the CREATE trial, the next steps for research into inflammatory myofibroblastic tumor, and the regulatory challenges for approval of drugs for rare cancers.
During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.
An analysis of patients who presented to MD Anderson Cancer Center’s dermatology clinic following treatment with anti–PD-1/PD-L1 treatment suggests a potential association between the development of cutaneous squamous cell carcinoma lesions and PD-1/PD-L1 checkpoint inhibition.
An analysis of immunologic biomarkers in a phase II trial of patients with advanced colorectal cancer treated with chemotherapy and PD-1 checkpoint inhibition identified several factors associated with a patient’s beneficial response to the chemo-immunotherapy regimen, according to findings presented during the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Results from a two-part, phase I dose-escalation and -expansion trial involving mogamulizumab in combination with durvalumab or tremelimumab for the treatment of patients with advanced solid tumors demonstrated mild-to-moderate adverse events that were tolerable and manageable, according to Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, during his presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
A peptide-based personalized vaccine demonstrated encouraging signals of efficacy and was well tolerated in patients with newly diagnosed glioblastoma, according to the results of the phase I GAPVAC-101 trial.
Stephanie K. Dougan, MD, assistant professor, Dana-Farber Cancer Institute and Harvard Medical School, discusses the idea of augmenting T cell immunity in tumors that are poorly immunogenic, such as pancreatic cancer.
The CD8-tracer 89Zr-IAB22M2C, an anti-CD8 radiolabeled minibody, was found to be safe, well-tolerated, and demonstrated whole-body biodistribution of CD8-positive T cells in tumors and reference tissues, according to first-in-human results presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.